Journal Publications

Export 131 results:
Author Title Type [ Year(Asc)]
Filters: Type is Journal Article  [Clear All Filters]
2009
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M et al. J Acquir Immune Defic Syndr, 2009 Nov 01, Volume 52, Issue 3, p.391-6, (2009)
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. Sabin C, Smith C, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K et al. HIV Med, 2009 Jan, Volume 10, Issue 1, p.35-43, (2009)
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips A, Bansi L, Gilson R, Easterbrook P et al. Haematologica, 2009 Jun, Volume 94, Issue 6, p.875-80, (2009)
Clinical epidemiology of HIV-associated end-stage renal failure in the UK. Bansi L, Hughes A, Bhagani S, Mackie N, Leen C, Levy J, Edwards S, Connolly J, Holt S, Hendry B et al. AIDS, 2009 Nov 27, Volume 23, Issue 18, p.2517-21, (2009)
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Geretti A, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D and Dunn D. Clin Infect Dis, 2009 May 01, Volume 48, Issue 9, p.1296-305, (2009)
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo A, Mocroft A, Bonnet F, Clifford G, Karafoulidou A et al. Antivir Ther, 2009, Volume 14, Issue 8, p.1065-74, (2009)
Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Murillo A, Mocroft A, Bonnet F, Clifford G, Touloumi G et al. AIDS, 2009 Sep 24, Volume 23, Issue 15, p.2029-37, (2009)
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Kesselring A, Wit F, Sabin C, Lundgren J, M Gill J, Gatell J, Rauch A, Montaner J, de Wolf F, Reiss P et al. AIDS, 2009 Aug 24, Volume 23, Issue 13, p.1689-99, (2009)
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? Grant A, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M et al. AIDS, 2009 Nov 27, Volume 23, Issue 18, p.2507-15, (2009)
Virological response to initial antiretroviral regimens containing abacavir or tenofovir. Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J et al. J Infect Dis, 2009 Sep 01, Volume 200, Issue 5, p.710-4, (2009)
2008
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? Bansi L, Benzie A, Phillips A, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R et al. AIDS, 2008 Jan 30, Volume 22, Issue 3, p.349-56, (2008)
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3. Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J, Fisher M, Orkin C et al. J Acquir Immune Defic Syndr, 2008 Feb 01, Volume 47, Issue 2, p.202-5, (2008)
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A et al. Antivir Ther, 2008, Volume 13, Issue 5, p.675-85, (2008)
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. Easterbrook P, Phillips A, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn D et al. HIV Med, 2008 Jan, Volume 9, Issue 1, p.47-56, (2008)
Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Dunn D, Geretti A, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin C and Phillips A. Antivir Ther, 2008, Volume 13, Issue 6, p.771-7, (2008)
Response to combination antiretroviral therapy: variation by age. Sabin C, Smith C, Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A et al. AIDS, 2008 Jul 31, Volume 22, Issue 12, p.1463-73, (2008)
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. Lee K, Dunn D, Gilson R, Porter K, Bansi L, Hill T, Phillips A, Sabin C, Schwenk A, Leen C et al. AIDS, 2008 Oct 01, Volume 22, Issue 15, p.1943-50, (2008)
What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? Grover D, Copas A, Green H, Edwards S, Dunn D, Sabin C, Phillips A, Allen E and Pillay D. J Antimicrob Chemother, 2008 Mar, Volume 61, Issue 3, p.705-13, (2008)
2007
CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. Stöhr W, Dunn D, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P, Fisher M, Johnson M et al. HIV Med, 2007 Apr, Volume 8, Issue 3, p.135-41, (2007)
Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy. Nebbia G, Sabin C, Dunn D and Geretti A. J Antimicrob Chemother, 2007 May, Volume 59, Issue 5, p.1013-6, (2007)
Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. . AIDS, 2007 May 11, Volume 21, Issue 8, p.1035-9, (2007)
HIV diagnosis at CD4 count above 500 cells/mm3 and progression to below 350 cells/mm3 without antiretroviral therapy. . J Acquir Immune Defic Syndr, 2007 Nov 01, Volume 46, Issue 3, p.275-8, (2007)
HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. Phillips A, Sabin C, Pillay D and Lundgren J. HIV Med, 2007 Nov, Volume 8, Issue 8, p.536-46, (2007)
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. Benzie A, Bansi L, Sabin C, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M et al. AIDS, 2007 Jul 11, Volume 21, Issue 11, p.1423-30, (2007)
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. Phillips A, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J et al. AIDS, 2007 Aug 20, Volume 21, Issue 13, p.1717-21, (2007)